PR Newswire Asia's news > Medical/Pharmaceuticals

 |   Title only   |   Print    Next page > 
     
Nilesh Shah joins Illumina as Head of Region, AMEA
SINGAPORE , Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of Nilesh Shah as Head of ...
2025-08-19T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
SHANGHAI and HONG KONG , Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated ...
2025-08-19T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Tigermed Receives MSCI ESG AAA Rating
HANGZHOU, China , Aug. 19, 2025 /PRNewswire/ -- Tigermed is proud to announce that it has been awarded an MSCI Environmental, Social, and Governance (ESG) Rating of AAA, the highest rating in the ...
2025-08-19T    Health Care/Hospital   Medical/Pharmaceuticals 
Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease
Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real ...
2025-08-19T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered ...
2025-08-19T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
openRxiv names Dr. Tracy Teal first CEO to advance open science
Scientist and nonprofit leader who previously led The Carpentries and Dryad to lead the organization that oversees bioRxiv and medRxiv. ...
2025-08-19T    Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Aon Announces Strategic Investment in eMed to Scale GLP-1 Population Health Platform
Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost adherence, retention and deliver breakthrough health outcomes with cost savings ...
2025-08-18T    Banking/Financial Service   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Datasea Achieves Breakthrough in Acoustic Technology, Accelerating Billion-Dollar Commercialization in Healthcare
DTSS' Acoustic innovation Addresses the Healthcare Application Market Projected to Exceed $100 Billion in China and Approach $90 Billion Globally by 2030 ...
2025-08-18T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).
This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted. DXVX is taking the lead in business development, with several ...
2025-08-18T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
BEIJING , Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, ...
2025-08-18T    Banking/Financial Service   Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
  Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.